Indocyanine Green and near infrared fLuorescence in paediatric Oncology surgery
Key facts
- Where
- Utrecht, HollandiaSee the site
- Phase
- 2. fázis
Where in Hollandia
- Prinses Maxima Centrum voor Kinderoncologie B.V.Utrecht, HollandiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- The University Of Birmingham
- Trial code
- EU 2024-514089-37-00
- Record updated
- 2026. április 30.
- Original description
• To identify number of lymph nodes removed in patients having a nephroureterectomy for renal cancer where surgery includes the use of ICG/NIRF for lymph node harvest and compare this data to those who have had the same surgery but without the use of ICG/NIRF • To identify number of lymph nodes removed during retroperitoneal lymph node dissection (RPLND) for paratesticular rhabdomyosarcoma in patients having ICG guided nodal harvestRead full original descriptionShow less
GLO-Surgery: Indocyanine Green and near infrared fLuorescence in paediatric Oncology surgery
• To identify number of lymph nodes removed in patients having a nephroureterectomy for renal cancer where surgery includes the use of ICG/NIRF for lymph node harvest and compare this data to those who have had the same surgery but without the use of ICG/NIRF • To identify number of lymph nodes removed during retroperitoneal lymph node dissection (RPLND) for paratesticular rhabdomyosarcoma in patients having ICG guided nodal harvest
Inclusion: Undergoing surgery via open laparotomy and/or thoracotomy, minimally invasive thoracoscopic, transperitoneal or retroperitoneoscopic surgery; Documented negative pregnancy test for female patients of childbearing potential within 7 days of trial entry; Sexually active male and female patients of childbearing potential must agree to use adequate and highly effective contraception while on study up until discharge; Written informed consent from the patient, parent or guardian; Cohort 2: Any renal tumour requiring surgical resection and retroperitoneal lymph node sampling; Cohort 3: Histologically confirmed or presumed diagnosis of para-testicular RMS (ptRMS) with the intention to sample nodes from the ipsilateral retroperitoneum according to template dissection. Otherwise known as Retroperitoneal Lymph Node Dissection (RPLND).
Exclusion: Cohort 2: Have entered a previous randomisation within Cohort 1; Cohort 3: Have entered a previous randomisation within Cohort 1; Have entered a previous randomisation within the same cohort; Allergic to ICG; Allergic to iodine or iodides; eGFR <15 ml/min/1.73 m2; Cohort 2: Renal tumour requiring extensive retroperitoneal or hilar dissection to access normal renal parenchyma for the ICG injection as this could damage the lymphatic vessels; Due to receive radioactive iodine as part of treatment; Known Hyperthyroidism; Female patients who are breastfeeding; Neonates requiring exchange transfusion; Cohort 2: Kidney wholly replaced by tumour on pre-operative imaging.